LakeShore Biopharma Calls Extraordinary General Meeting
Ticker: LSBWF · Form: 6-K · Filed: Sep 10, 2024 · CIK: 1946399
| Field | Detail |
|---|---|
| Company | Lakeshore Biopharma CO., LTD. (LSBWF) |
| Form Type | 6-K |
| Filed Date | Sep 10, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, corporate-action, foreign-issuer
TL;DR
Lakeshore Biopharma is holding a shareholder meeting in Sept 2024 - expect news.
AI Summary
LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) announced an Extraordinary General Meeting to be held in September 2024. The company is located in Beijing, PRC, and its principal executive offices are at Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park.
Why It Matters
This meeting likely concerns significant corporate decisions or changes that could impact the company's future direction and shareholder value.
Risk Assessment
Risk Level: low — The filing is a routine announcement of a shareholder meeting and does not contain significant financial or operational news.
Key Players & Entities
- LakeShore Biopharma Co., Ltd. (company) — Registrant
- YS Biopharma Co., Ltd. (company) — Former company name
- YishengBio Co., Ltd (company) — Former company name
- September 2024 (date) — Month of report and meeting
- 001-41598 (company) — SEC file number
FAQ
What is the purpose of the Extraordinary General Meeting?
The filing does not specify the exact purpose of the Extraordinary General Meeting, only that it is scheduled for September 2024.
When was LakeShore Biopharma Co., Ltd. formerly known as?
LakeShore Biopharma Co., Ltd. was formerly known as YS Biopharma Co., Ltd. and YishengBio Co., Ltd.
What is the company's primary business address?
The company's principal executive offices are located at Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District, Beijing, PRC.
Under which SEC Act does this filing fall?
This filing is made pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Does the company file annual reports under Form 20-F or 40-F?
The registrant indicates it files annual reports under Form 20-F.
Filing Stats: 196 words · 1 min read · ~1 pages · Grade level 11.7 · Accepted 2024-09-10 08:15:08
Filing Documents
- ea0214070-6k_lakeshore.htm (6-K) — 12KB
- ea021407001ex99-1_lakeshore.htm (EX-99.1) — 11KB
- ea021407001ex99-2_lakeshore.htm (EX-99.2) — 20KB
- ea021407001ex99-3_lakeshore.htm (EX-99.3) — 20KB
- 0001213900-24-077130.txt ( ) — 65KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission file number: 001-41598 LAKESHORE BIOPHARMA CO., LTD (Exact name of registrant as specified in its charter) Building No. 2, 38 Yongda Road Daxing Biomedical Industry Park Daxing District, Beijing, PRC Tel: 010-89202086 (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F EXHIBIT INDEX Exhibit No. Description 99.1 Press Release - Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024 99.2 Notice of Extraordinary General Meeting of Shareholders 99.3 Form of Proxy for Extraordinary General Meeting of Shareholders 1 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LakeShore Biopharma Co., Ltd By: /s/ Rachel Yu Name: Rachel Yu Title: Director and Chief Financial Officer Date: September 10, 2024 2